The Global Leukemia Therapeutics Market has been estimated at USD 5.60 Billion in 2016 and is projected to reach USD 8.82 Billion by 2021, at a CAGR of 9.5% during the forecast period from 2016 to 2021. Leukemia is a type of blood cancer which results in abnormal production of leukocytes or WBC. They crowd the bone marrow and other organs such as liver, spleen, and kidneys through blood and prevent its normal functions. The disease is commonly caused due to the high exposure to radiations, unhealthy lifestyle, genetic factors, and environmental conditions.
Browse market data tables and in-depth TOC of the Global Leukemia Therapeutics Market to 2021 @ http://www.marketdataforecast.com/market-reports/global-leukemia-therapeutics-market-822/
The market for Leukemia Therapeutics globally is driven mainly due increasing aging population which is resulting in increasing prevalence of leukemia, as the disease occurrence is mainly seen in middle-aged people and senior citizens. Also, with recent breakthroughs in this area by Research teams across the globe, the scope for treatments is also widening. But, high treatment costs and drug costs are the issues hindering the growth of the market.
Global market for Leukemia Therapeutics is segmented based on disease condition, diagnosis, treatments and drugs. By disease condition, the market is further sub-segmented into chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia and acute myeloid leukemia. By diagnosis, the market is further sub-segmented into CT scan, biopsy and MRI. By treatments, the market is further sub-segmented into chemotherapy, radiation therapy, immunotherapy, surgery, targeted therapy, bone marrow transplant and stem cell therapy. By drugs, the market is further sub-segmented into Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat. By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in leukemia therapeutic market. Gleevec was one of the major market growth contributors, in the drugs category.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/global-leukemia-therapeutics-market-822/request-sample
Geographically, Global market for Leukemia Therapeutics is segmented into North America, Asia Pacific, Latin America, Europe, and Africa & Middle-East. North America holds the largest share of the global market, followed by Europe. Factors such as rising prevalence of cervical cancer, growing awareness of cervical cancer screening programs, and government support are driving the growth of the Leukemia therapeutics market in the North American region. Asia Pacific market is growing at very high rate, due to rising consumer market, increasing aging population, and rising awareness for healthcare among the population in developing nations of the region.
F. Hoffmann-La Roche Ltd , GlaxoSmithKline Pharmaceuticals Limited , Novartis International AG, Bristol-Myers Squibb , Eisai Co. Ltd, Biogen Idec , ERYtech Pharma , Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc. are the major players of Global Leukemia Therapeutics market.
Avail discount @ http://www.marketdataforecast.com/market-reports/global-leukemia-therapeutics-market-822/request-discount
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: [email protected]
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases